Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free AIDX Stock Alerts

20/20 Biolabs (AIDX) Competitors

20/20 Biolabs logo
$0.98 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.02 +0.04 (+4.08%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AIDX vs. CAST, BGSF, GMHS, BRAG, and ONMD

Should you buy 20/20 Biolabs stock or one of its competitors? MarketBeat compares 20/20 Biolabs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 20/20 Biolabs include FreeCast (Direct Listing) (CAST), BGSF (BGSF), Gamehaus (GMHS), Bragg Gaming Group (BRAG), and OneMedNet (ONMD). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

20/20 Biolabs (NASDAQ:AIDX) and FreeCast (Direct Listing) (NASDAQ:CAST) are both small-cap services companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 410.20%. FreeCast (Direct Listing) has a consensus price target of $6.00, suggesting a potential upside of 494.06%. Given FreeCast (Direct Listing)'s stronger consensus rating and higher probable upside, analysts clearly believe FreeCast (Direct Listing) is more favorable than 20/20 Biolabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
FreeCast (Direct Listing)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, 20/20 Biolabs had 3 more articles in the media than FreeCast (Direct Listing). MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for FreeCast (Direct Listing). 20/20 Biolabs' average media sentiment score of 0.27 beat FreeCast (Direct Listing)'s score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
FreeCast (Direct Listing)
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
FreeCast (Direct Listing) N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M5.09N/AN/AN/A
FreeCast (Direct Listing)$565.17K73.88N/AN/AN/A

0.0% of FreeCast (Direct Listing) shares are owned by institutional investors. 17.5% of FreeCast (Direct Listing) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

FreeCast (Direct Listing) beats 20/20 Biolabs on 5 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to BGSF?

20/20 Biolabs (NASDAQ:AIDX) and BGSF (NYSE:BGSF) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

20/20 Biolabs has a net margin of 0.00% compared to BGSF's net margin of -11.98%. 20/20 Biolabs' return on equity of 0.00% beat BGSF's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
BGSF -11.98%-18.91%-12.30%

20/20 Biolabs has higher earnings, but lower revenue than BGSF.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M5.09N/AN/AN/A
BGSF$93.31M0.60-$11.43M-$1.00N/A

20/20 Biolabs presently has a consensus target price of $5.00, suggesting a potential upside of 410.20%. Given 20/20 Biolabs' higher possible upside, research analysts plainly believe 20/20 Biolabs is more favorable than BGSF.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
BGSF
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

37.2% of BGSF shares are owned by institutional investors. 8.0% of BGSF shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 20/20 Biolabs had 3 more articles in the media than BGSF. MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for BGSF. 20/20 Biolabs' average media sentiment score of 0.27 beat BGSF's score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BGSF
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

20/20 Biolabs beats BGSF on 8 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gamehaus?

20/20 Biolabs (NASDAQ:AIDX) and Gamehaus (NASDAQ:GMHS) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

20/20 Biolabs presently has a consensus target price of $5.00, suggesting a potential upside of 410.20%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Gamehaus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Gamehaus
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, 20/20 Biolabs had 3 more articles in the media than Gamehaus. MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for Gamehaus. 20/20 Biolabs' average media sentiment score of 0.27 beat Gamehaus' score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gamehaus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gamehaus has higher revenue and earnings than 20/20 Biolabs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M5.09N/AN/AN/A
Gamehaus$118.05M0.46$3.96M$0.0911.22

63.7% of Gamehaus shares are owned by institutional investors. 27.7% of Gamehaus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Gamehaus N/A N/A N/A

Summary

20/20 Biolabs beats Gamehaus on 6 of the 9 factors compared between the two stocks.

How does 20/20 Biolabs compare to Bragg Gaming Group?

20/20 Biolabs (NASDAQ:AIDX) and Bragg Gaming Group (NASDAQ:BRAG) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, 20/20 Biolabs had 4 more articles in the media than Bragg Gaming Group. MarketBeat recorded 4 mentions for 20/20 Biolabs and 0 mentions for Bragg Gaming Group. 20/20 Biolabs' average media sentiment score of 0.27 beat Bragg Gaming Group's score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Neutral
Bragg Gaming Group Neutral

4.0% of Bragg Gaming Group shares are held by institutional investors. 26.4% of Bragg Gaming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

20/20 Biolabs has higher earnings, but lower revenue than Bragg Gaming Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.05M5.09N/AN/AN/A
Bragg Gaming Group$119.98M0.34-$9.18M-$0.31N/A

20/20 Biolabs has a net margin of 0.00% compared to Bragg Gaming Group's net margin of -6.27%. 20/20 Biolabs' return on equity of 0.00% beat Bragg Gaming Group's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Bragg Gaming Group -6.27%-10.65%-6.92%

20/20 Biolabs presently has a consensus price target of $5.00, indicating a potential upside of 410.20%. Bragg Gaming Group has a consensus price target of $5.00, indicating a potential upside of 203.03%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities analysts clearly believe 20/20 Biolabs is more favorable than Bragg Gaming Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bragg Gaming Group
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Summary

20/20 Biolabs beats Bragg Gaming Group on 9 of the 12 factors compared between the two stocks.

How does 20/20 Biolabs compare to OneMedNet?

OneMedNet (NASDAQ:ONMD) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, OneMedNet and OneMedNet both had 4 articles in the media. OneMedNet's average media sentiment score of 1.12 beat 20/20 Biolabs' score of 0.27 indicating that OneMedNet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OneMedNet
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
20/20 Biolabs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

20/20 Biolabs has higher revenue and earnings than OneMedNet.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OneMedNet$1.36M36.15-$2.80M-$0.07N/A
20/20 Biolabs$2.05M5.09N/AN/AN/A

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 410.20%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than OneMedNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OneMedNet
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

20/20 Biolabs has a net margin of 0.00% compared to OneMedNet's net margin of -254.13%.

Company Net Margins Return on Equity Return on Assets
OneMedNet-254.13% N/A -383.90%
20/20 Biolabs N/A N/A N/A

1.0% of OneMedNet shares are held by institutional investors. 46.2% of OneMedNet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats OneMedNet on 6 of the 10 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIDX vs. The Competition

Export
Metric20/20 BiolabsServices – Research, Development, Testing Labs IndustryServices SectorNASDAQ Exchange
Market Cap$10.40M$10.06M$978.18M$12.34B
Dividend YieldN/AN/A5.12%5.28%
P/E RatioN/AN/A9.2525.66
Price / Sales5.093.1836.5386.31
Price / CashN/AN/A381.8256.67
Price / BookN/A0.224.357.14
Net IncomeN/A-$15.16M-$6.42M$335.98M
7 Day Performance-26.87%-11.06%3.07%4.15%
1 Month Performance-40.24%-22.31%-5.06%2.54%
1 Year PerformanceN/AN/A48.28%35.06%

20/20 Biolabs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIDX
20/20 Biolabs
N/A$0.98
flat		$5.00
+410.2%		N/A$10.40M$2.05MN/A14
CAST
FreeCast (Direct Listing)
2.7739 of 5 stars		$1.33
-7.6%		$6.00
+350.8%		N/A$55.57M$616.15KN/A48
BGSF
BGSF
0.7183 of 5 stars		$5.18
+0.4%		N/A+18.4%$55.53M$93.31MN/A400
GMHS
Gamehaus
0.8747 of 5 stars		$0.95
-8.8%		N/A-21.7%$50.84M$113.59M10.54N/A
BRAG
Bragg Gaming Group
2.6358 of 5 stars		$1.77
+7.9%		$5.00
+182.5%		-62.1%$44.32M$119.98MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel